Answers are grounded in this paper and cite their sources.
Development of MTMSCRC improves predictions for prognosis and chemotherapy benefits in colorectal cancer patients, indicating better clinical decisions.
The current tumor‒node‒metastasis (TNM) staging system cannot provide sufficient information for prognosis and chemotherapy benefits in patients with colorectal cancer (CRC). The tumor microenvironment plays a critical role in disease progression and therapeutic response. Here, we developed and validated a multimodal tumor microenvironment signature of CRC (MTMSCRC) using 1314 CRC patients to enhance prognosis and chemotherapy benefit predictions. We found that the MTMSCRC is an independent predictor of prognosis. Furthermore, incorporating the MTMSCRC and clinicopathological characteristics into the integrated nomograms significantly outperformed traditional models and the TNM staging system. Shapley values identified the MTMSCRC as the most important predictor. Moreover, chemotherapy had no impact on prognosis in nomogram-predicted low-risk score patients but was associated with improved prognosis in medium and high-risk score patients. In summary, the MTMSCRC is a valuable prognostic predictor in CRC patients and the integrated nomogram may help identify those who could benefit from chemotherapy.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: